ReviewCurrent oncology reports2002
Prevention of liver cancer.
Review in Current oncology reports, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 90 citations in OpenAlex.
- Global trends and thematic evolution of nursing in liver cancer: a bibliometric analysis of the web of science core collection (1944-2025).Discover oncology · 2026Article
- Ras-related associated with diabetes genes for biomarker-based therapeutics in cancer: A comparative evolutionary genomic study.Saudi medical journal · 2024Article
- Anti-carcinogenic effects and mechanisms of actions ofAmerican journal of cancer research · 2024Article
- Review
- Article
- Protective Effect of Boswellic Acids against Doxorubicin-Induced Hepatotoxicity: Impact on Nrf2/HO-1 Defense Pathway.Oxidative medicine and cellular longevity · 2018Article
- Terpenes from Forests and Human Health.Toxicological research · 2017Review
- Therapeutic properties of green tea against environmental insults.The Journal of nutritional biochemistry · 2017Review
- Roles of p53 in extrinsic factor-induced liver carcinogenesis.Hepatoma research · 2017Article
- A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer.Pharmaceuticals (Basel, Switzerland) · 2016Article
- Article
- Cancer chemoprevention by dietary chlorophylls: a 12,000-animal dose-dose matrix biomarker and tumor study.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2012Article
- Physical properties of gum karaya-starch-essential oil patches.AAPS PharmSciTech · 2010Article
- Hydrogen peroxide is a second messenger in phase 2 enzyme induction by cancer chemopreventive dithiolethiones.Chemical research in toxicology · 2009Article
- Chemopreventive effect of selenium and Chinese medicinal herbs on N-nitrosobis(2-oxopropyl)amine-induced hepatocellular carcinoma in Syrian hamsters.Liver international : official journal of the International Association for the Study of the Liver · 2008Article
- Bioinformatic screening of human ESTs for differentially expressed genes in normal and tumor tissues.BMC genomics · 2006Article
- Inhibition of growth and metastasis of human gastric cancer implanted in nude mice by d-limonene.World journal of gastroenterology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is among the most prevalent and deadly cancers worldwide. Prominent risk factors for HCC include viral hepatitis infection; dietary exposure to hepatotoxic contaminants such as aflatoxins; alcoholism; smoking; and male gender. This review highlights ongoing efforts in HCC prevention. Strategies include vaccination against, and treatment of, viral hepatitis infection. In addition to interferon alpha, an acyclic retinoid (all-trans-3,7,11, 15-tetramethyl-2,4,6,10,14-hexadecapentanoic acid), glycyrrhizin and ginseng are currently under clinical investigation for HCC prevention in Japanese hepatitis C patients. Several recent clinical studies in a Chinese region of pervasive aflatoxin contamination also support the approach of favorably altering aflatoxin metabolism and excretion using the chemopreventive agents oltipraz or chlorophyllin. Agents exhibiting chemopreventive efficacy in preclinical HCC models include vitamins A, D, and E, herbal extracts, a 5alpha-reductase inhibitor, green tea, and D-limonene. Efforts to elucidate the molecular lesions and processes underlying HCC development have identified several putative molecular targets for preventive interventions. These include genes and gene products controlling viral replication, carcinogen metabolism, signal transduction, cell-cycle arrest, apoptosis, proliferation, and oxidative stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.